Search clinical trials for: nab-paclitaxel and gemcitabine

Total 8124 results

Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Breast Cancer

France, United States, Spain, United Kingdom, Australia
Queen Mary University of London
Medical Research Council; Celgene

Not yet recruiting

Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer (STARPAC2)

Pancreatic Cancer
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

Lung Cancer

United States, Australia, Peru, Puerto Rico
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (ATNPA)

Locally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic Neoplasm

China
Washington University School of Medicine

Completed

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Adenocarcinoma | Pancreatic Neoplasms

United States
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Korean Gynecologic Oncology Group

Unknown

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Korea, Republic of
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
University of Utah

Active, not recruiting

Assessing Adolescent Use of Nexplanon Over Time

Contraception

United States
Shantou Central Hospital

Recruiting

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Breast Cancer

China
MedSIR

Withdrawn

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (POLTER)

Advanced Breast Cancer
Priyanka Sharma
Novartis Pharmaceuticals

Completed

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Breast Cancer

United States
Liza Villaruz, MD

Completed

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Head and Neck Squamous Cell Carcinoma

China
HonorHealth Research Institute
Mayo Clinic; University of California, San Diego; Cancer Research UK; Stand Up... and other collaborators

Completed

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD)

Adenocarcinoma | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreas Metastases

United States
Fox Chase Cancer Center

Recruiting

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | Small-cell Lung Cancer

United States
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Breast Cancer

China, United States, Spain, Hungary, Israel, Korea, Republic of, Taiwan, Belgium, Austria, Russian Federation, Switzerland, Portugal, France, Canada, Italy, United Kingdom, Greece, Japan, Germany, Sweden
NovoCure Ltd.

Active, not recruiting

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Pancreas Adenocarcinoma

United States, China, Belgium, Czechia, Korea, Republic of, Spain, Hong Kong, France, Australia, Italy, Hungary, Germany, Croatia, Canada, Mexico, Israel, Austria, Switzerland, Brazil, Poland
Halozyme Therapeutics

Terminated

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Carcinoma

Korea, Republic of, United States, Taiwan, United Kingdom, Israel, France, Germany, Netherlands, Canada, Spain, Australia, Brazil, Belgium, Croatia, Czechia, Denmark, Estonia, Hungary, Italy, Latvia, Lithuania, Poland
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal-junction Cancer

China
EQRx International, Inc.

Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NSCLC

United States
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
University of Colorado, Denver
Cancer League of Colorado

Withdrawn

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Metastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene Mutation

United States
Fudan University

Active, not recruiting

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Triple-Negative Breast Cancer

China
Fudan University

Unknown

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Stage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic Cancer

China
AGO Study Group
GERCOR - Multidisciplinary Oncology Cooperative Group; Nordic Society of Gynaecological...

Completed

Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (AGO-OVAR9)

Ovarian Cancer | Fallopian Tube Cancer

Norway, Germany, France, Denmark
Colette Shen
AstraZeneca; University of North Carolina, Chapel Hill

Recruiting

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA)

Breast Cancer | Brain Metastases, Adult

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms, Nerve... and other conditions

Italy, Korea, Republic of, Australia, Spain, Argentina, Belgium, Brazil, France, Portugal, United Kingdom, United States, Japan, Mexico, Poland, Norway, Costa Rica, Switzerland, Netherlands, Germany, Sweden, Turkey, Ireland, Panama
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Fudan University

Not yet recruiting

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Pancreatic Adenocarcinoma
Barts & The London NHS Trust
King's College London; Cambridge University Hospitals NHS Foundation Trust; Medical... and other collaborators

Completed

Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)

Pancreatic Adenocarcinoma

United Kingdom
The Cooper Health System

Terminated

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the Pancreas

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Breast Adenocarcinoma | Inflammatory Breast Carcinoma

United States
Fudan University

Recruiting

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer (PTCA199-5)

Chemotherapy-induced Nausea and Vomiting | Pancreatic Cancer Stage IV

China
Genentech, Inc.
Chugai Pharmaceutical Co.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Gastric Cancer | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of, Spain, Japan, New Zealand, Australia, United States, Italy, Brazil
Susan E. Bates

Recruiting

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

Pancreas Cancer

United States
Sierra Oncology LLC - a GSK company

Terminated

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Baylor Research Institute

Completed

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

Pancreatic Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Neoplasms

Italy, United States, Australia, Canada, Chile, Israel, Korea, Republic of, Spain
Jianjun Yang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer

Gastric Cancer

China
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, Australia
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Breast Cancer

Israel, Italy, Spain, United States, Belgium, Czechia, Australia, United Kingdom, Korea, Republic of, Romania, France, Taiwan, Latvia
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine

Search clinical trials for: nab-paclitaxel and gemcitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations